The Debate Continues, Is IAD or CAD Superior for the Treatment of Men with Castrate Resistant Prostate Cancer?
A new randomized study (FinnProstate Study VII) on the merits of intermittent androgen deprivation (IAD) compared to continuous androgen therapy (CAD) contradicts the recent revelations from the last ASCO presentation (Hussain et.al) where the clear conclusion was that CAD was superior to IAD. At the ASCO conference Dr. Hussain’s study concluded that IAD was significantly [...]